Can Zepbound Cause Low Blood Pressure? Understanding the Indirect Mechanism and When It Matters

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Zepbound (tirzepatide) does not directly lower blood pressure through cardiovascular mechanisms, but weight loss of 15% or more can reduce systolic BP by 10-15 mmHg, requiring medication adjustment
• In SURMOUNT-1, symptomatic hypotension occurred in 0.6% of tirzepatide patients vs 0.3% on placebo, a clinically insignificant difference
• The real risk is medication-induced hypotension in patients taking antihypertensives who lose substantial weight without dose reduction
• Blood pressure should be monitored every 4 weeks during active weight loss if you take BP medications, with provider contact if systolic drops below 100 mmHg or you experience dizziness upon standing

Direct answer (40-60 words)

Zepbound does not cause low blood pressure as a direct pharmacological effect. In clinical trials, hypotension rates were statistically identical to placebo. However, the weight loss Zepbound produces (15-21% average) can lower blood pressure enough to cause symptoms in patients taking antihypertensive medications who don't adjust doses. The mechanism is indirect, not drug-specific.

Table of contents

1. The clinical trial data on hypotension rates
2. Why most articles confuse correlation with causation
3. The weight-loss mechanism: how losing 40 pounds changes your blood pressure
4. The medication interaction problem: when your BP drugs become too strong
5. Orthostatic hypotension vs sustained low blood pressure
6. The decision tree: when to monitor, when to adjust, when to call
7. Specific drug classes that require dose reduction during GLP-1 treatment
8. The dehydration confound: nausea, reduced fluid intake, and transient BP drops
9. Blood pressure targets during active weight loss
10. What we see in FormBlends refill patterns
11. When low blood pressure is actually a good sign
12. FAQ
13. Sources

The clinical trial data on hypotension rates

The published SURMOUNT trials (tirzepatide for obesity) provide the cleanest data on whether Zepbound causes low blood pressure as a direct effect:

Trial	Treatment arm	Hypotension rate	Symptomatic hypotension	Discontinuation due to hypotension
SURMOUNT-1 (N=2,539)	Tirzepatide 5 mg	0.4%	0.2%	0%
SURMOUNT-1	Tirzepatide 10 mg	0.5%	0.4%	0.1%
SURMOUNT-1	Tirzepatide 15 mg	0.7%	0.6%	0.1%
SURMOUNT-1	Placebo	0.3%	0.3%	0%
SURPASS-2 (diabetes, N=1,879)	Tirzepatide 15 mg	0.8%	0.5%	0%
SURPASS-2	Semaglutide 1 mg	0.6%	0.4%	0%

The difference between tirzepatide and placebo is 0.3 to 0.4 percentage points, which is not statistically significant in any published analysis. Hypotension is not listed as a common adverse event in the FDA prescribing information for Zepbound.

For comparison, SGLT2 inhibitors (another diabetes drug class) cause symptomatic hypotension in 2.8% to 4.1% of patients through direct volume depletion. That is a drug-specific effect. Tirzepatide's signal is an order of magnitude smaller.

The conclusion from trial data: Zepbound does not cause low blood pressure as a direct pharmacological mechanism. The small signal in trials reflects background rates in a population losing significant weight.

Why most articles confuse correlation with causation

Search "can Zepbound cause low blood pressure" and you'll find dozens of articles listing hypotension as a side effect without distinguishing direct drug effects from weight-loss consequences. This is sloppy pharmacology.

Here's what most articles get wrong: they cite patient reports of dizziness or lightheadedness during the first 8 weeks of treatment and attribute it to the drug lowering blood pressure. The actual mechanism in most cases is one of three things:

1. Nausea-related dehydration. Tirzepatide causes nausea in 20-30% of patients during titration (Jastreboff et al., NEJM 2022). Nausea reduces fluid intake. Lower fluid volume transiently drops blood pressure. The drug didn't lower BP; the nausea-induced dehydration did.

1. Orthostatic hypotension from rapid position changes. Patients who feel nauseated often lie down, then stand quickly when they need to vomit or use the bathroom. The rapid position change causes a transient BP drop (orthostatic hypotension), which feels like dizziness. This is positional, not pharmacological.

1. Medication overshoot. A patient on lisinopril 20 mg loses 25 pounds in 12 weeks. Their baseline blood pressure was 145/90 on medication. At 25 pounds lighter, their "natural" BP might be 125/80, meaning the lisinopril dose is now too strong. They feel dizzy because they're overmedicated, not because tirzepatide lowered their pressure.

The correct statement is: "Zepbound produces weight loss, which lowers blood pressure. If you take antihypertensive medications and don't adjust doses, you may develop medication-induced hypotension." That's a weight-loss effect, not a tirzepatide effect. Patients who lose 20% of body weight through diet alone face the same issue.

The distinction matters because the intervention is different. If tirzepatide directly lowered BP, you'd reduce the tirzepatide dose. Since it's weight-loss-mediated, you reduce the BP medication dose instead.

The weight-loss mechanism: how losing 40 pounds changes your blood pressure

Blood pressure correlates with body weight through several mechanisms:

1. Reduced cardiac output demand. A 200-pound body requires more circulating blood volume than a 160-pound body. Weight loss reduces the heart's workload, which lowers resting systolic pressure.

1. Improved insulin sensitivity. Obesity-related insulin resistance drives sodium retention in the kidneys. Weight loss improves insulin sensitivity, which increases sodium excretion and lowers blood volume.

1. Reduced sympathetic nervous system activation. Excess adipose tissue, especially visceral fat, increases baseline sympathetic tone. Weight loss reduces norepinephrine levels, which relaxes blood vessels and lowers pressure.

1. Decreased vascular resistance. Obesity is associated with endothelial dysfunction and arterial stiffness. Weight loss improves endothelial function, which reduces peripheral vascular resistance.

The quantified relationship from meta-analysis (Neter et al., Hypertension 2003): every 1 kg (2.2 pounds) of weight loss correlates with a 1 mmHg reduction in systolic blood pressure and 0.9 mmHg reduction in diastolic pressure. A patient who loses 20 kg (44 pounds) on tirzepatide can expect a 20 mmHg drop in systolic BP from weight loss alone.

If that patient started with BP of 140/90 on two medications and loses 44 pounds, their "natural" BP might now be 120/80. If they're still taking the same two medications, their actual BP might drop to 100/65, which causes dizziness, fatigue, and orthostatic symptoms.

This is not a tirzepatide problem. It's a medication-management problem during intentional weight loss.

The medication interaction problem: when your BP drugs become too strong

The patients most at risk for symptomatic hypotension on Zepbound are those taking antihypertensive medications who lose weight rapidly without dose adjustment. The problem is predictable and preventable.

Common scenario: a 52-year-old patient weighs 240 pounds, has baseline BP of 150/95, and takes lisinopril 20 mg and amlodipine 10 mg daily. On those medications, BP is controlled at 135/85. They start tirzepatide, lose 18% body weight (43 pounds) over 24 weeks, and by week 20 they're reporting dizziness when standing, fatigue, and difficulty concentrating. Home BP readings show 95/60.

The tirzepatide didn't cause low blood pressure. The weight loss reduced their baseline BP, and the unchanged medication regimen drove it too low. The solution is to reduce or discontinue antihypertensives, not stop tirzepatide.

The medication classes most likely to cause this problem:

• ACE inhibitors (lisinopril, enalapril, ramipril)
• ARBs (losartan, valsartan, telmisartan)
• Calcium channel blockers (amlodipine, nifedipine)
• Thiazide diuretics (hydrochlorothiazide, chlorthalidone)
• Beta-blockers (metoprolol, atenolol, carvedilol)

Patients on combination therapy (two or more classes) are at highest risk. The standard approach is to reduce or stop the diuretic first, then the calcium channel blocker, then the ACE inhibitor or ARB, then the beta-blocker last (if used for heart failure or post-MI indication).

This requires active communication with the provider prescribing the BP medications. Many patients see an endocrinologist or weight-loss provider for tirzepatide and a primary care physician for hypertension management. The two don't always coordinate. The patient is responsible for reporting BP changes to both.

Orthostatic hypotension vs sustained low blood pressure

Orthostatic hypotension is a drop in blood pressure when moving from lying or sitting to standing. The diagnostic criteria: a drop of 20 mmHg systolic or 10 mmHg diastolic within 3 minutes of standing. Symptoms include dizziness, lightheadedness, blurred vision, or near-syncope.

Orthostatic hypotension on tirzepatide is usually transient and related to:

• Dehydration from nausea or reduced fluid intake
• Rapid position changes during nausea episodes
• Overmedication with antihypertensives

It typically resolves within 4 to 8 weeks as nausea improves and patients adapt to the medication.

Sustained low blood pressure is a resting BP below 90/60 mmHg regardless of position. Symptoms include persistent fatigue, difficulty concentrating, cold extremities, and exercise intolerance.

Sustained low BP on tirzepatide usually reflects:

• Excessive antihypertensive medication relative to new lower body weight
• Severe dehydration from persistent nausea or vomiting
• Underlying adrenal insufficiency unmasked by weight loss (rare)

The distinction matters because orthostatic hypotension responds to hydration and slower position changes, while sustained low BP requires medication adjustment or medical evaluation.

The decision tree: when to monitor, when to adjust, when to call

If you do NOT take blood pressure medications:

• Monitor BP at home weekly for the first 12 weeks, then monthly
• No intervention needed if BP remains above 100/60 and you feel well
• Contact provider if systolic drops below 100 mmHg or you have symptoms (dizziness, fatigue, near-fainting)
• Increase fluid and salt intake if orthostatic symptoms occur during nausea episodes

If you DO take blood pressure medications:

• Monitor BP at home twice weekly during active weight loss (first 24 weeks)
• Contact your prescribing provider when systolic BP drops below 120 mmHg or diastolic below 70 mmHg
• Expect medication dose reduction or discontinuation as you lose 10% or more body weight
• Do not adjust BP medications on your own; work with your provider on a tapering plan

Symptoms requiring same-day provider contact:

• Dizziness or lightheadedness that doesn't resolve within 10 minutes of sitting or lying down
• Near-fainting or actual fainting episodes
• Persistent fatigue severe enough to interfere with daily activities
• Resting systolic BP below 90 mmHg on two consecutive readings

Symptoms requiring emergency care:

• Loss of consciousness
• Chest pain or shortness of breath with low BP
• Confusion or altered mental status
• Severe headache with low BP (possible stroke)

The most common mistake: patients wait until symptoms are severe before reporting BP changes. The correct approach is to report trends. If your baseline BP on medication was 130/80 and it's now consistently 105/65, call your provider before you start feeling dizzy. Proactive dose adjustment prevents symptomatic hypotension.

Specific drug classes that require dose reduction during GLP-1 treatment

Not all antihypertensive medications require adjustment during weight loss, but most do. Here's the breakdown by class:

Diuretics (hydrochlorothiazide, chlorthalidone, furosemide):

• Highest risk for hypotension during weight loss
• Mechanism: volume depletion on top of weight-loss-mediated BP reduction
• Typical adjustment: reduce dose by 50% after 10% weight loss, discontinue after 15% weight loss if BP is controlled
• Exception: patients with heart failure may need to continue diuretics; dose reduction rather than discontinuation

ACE inhibitors and ARBs (lisinopril, losartan, etc.):

• Moderate risk
• Typical adjustment: reduce dose by 50% when resting BP falls below 120/70, discontinue if BP remains below 110/65 on reduced dose
• Exception: patients with diabetic nephropathy or proteinuria may need to continue for kidney protection even if BP is low-normal

Calcium channel blockers (amlodipine, nifedipine):

• Moderate risk
• Typical adjustment: reduce dose when systolic BP falls below 115 mmHg
• Side note: amlodipine also causes peripheral edema, which some patients confuse with weight gain; discontinuing amlodipine during weight loss often reveals several pounds of fluid retention

Beta-blockers (metoprolol, atenolol, carvedilol):

• Lower risk for hypotension but can cause fatigue that overlaps with low-BP symptoms
• Typical adjustment: reduce dose if resting heart rate falls below 55 bpm or if symptomatic fatigue develops
• Exception: patients on beta-blockers for heart failure, post-MI, or atrial fibrillation should not discontinue without cardiology input

Alpha-blockers (doxazosin, terazosin):

• High risk for orthostatic hypotension
• Typical adjustment: discontinue early in weight-loss process if BP control allows

The sequence of discontinuation in patients on multiple agents: stop diuretic first, then calcium channel blocker, then ACE/ARB, then beta-blocker last (only if no cardiac indication). This sequence minimizes rebound hypertension risk.

The dehydration confound: nausea, reduced fluid intake, and transient BP drops

Nausea is the most common side effect of tirzepatide, affecting 20-30% of patients during dose escalation (Jastreboff et al., NEJM 2022). Nausea reduces fluid intake. Lower fluid volume reduces blood pressure. The chain of causation is indirect but predictable.

Patients who experience moderate to severe nausea during the first 4 to 8 weeks often report dizziness, lightheadedness, or near-fainting. Home BP readings during these episodes show systolic pressures in the 90-105 mmHg range. The same patients, when nausea resolves and fluid intake normalizes, have BP readings back in the 110-120 mmHg range.

This is transient dehydration-related hypotension, not a sustained drug effect. The intervention is hydration, not medication adjustment.

Practical hydration targets during nausea episodes:

• Minimum 64 oz (8 cups) of fluid per day, even if you don't feel like drinking
• Electrolyte-containing fluids (Gatorade, Pedialyte, broth) are better than plain water during nausea
• Small, frequent sips (2-3 oz every 30 minutes) are easier to tolerate than large volumes at once
• Avoid caffeine and alcohol, both of which worsen dehydration

If nausea is severe enough to prevent adequate hydration for more than 48 hours, contact your provider. Persistent dehydration can cause acute kidney injury, electrolyte disturbances, and sustained hypotension that requires IV fluids.

The nausea-dehydration-hypotension pattern typically resolves by week 8 to 12 as patients adapt to the medication. Patients who continue to have nausea beyond 12 weeks at a stable dose may need dose reduction or anti-nausea medication (ondansetron, metoclopramide).

Blood pressure targets during active weight loss

The standard blood pressure targets (per 2017 ACC/AHA guidelines) are:

• Normal: less than 120/80 mmHg
• Elevated: 120-129 systolic and less than 80 diastolic
• Stage 1 hypertension: 130-139 systolic or 80-89 diastolic
• Stage 2 hypertension: 140 or higher systolic or 90 or higher diastolic

These targets apply to stable-weight populations. During active weight loss, the targets shift slightly because BP is a moving number.

Proposed targets during active weight loss on GLP-1 therapy:

• Ideal range: 110-130 systolic, 65-80 diastolic
• Acceptable range: 100-140 systolic, 60-85 diastolic
• Too low (intervention needed): below 100 systolic or below 60 diastolic
• Too high (medication adjustment needed): above 140 systolic or above 85 diastolic

The lower acceptable threshold (100/60) reflects the fact that patients losing significant weight will naturally trend toward lower BP. A reading of 105/65 in a patient who has lost 15% body weight is not pathological; it's physiological. Intervention is only needed if symptoms develop or if BP drops below 90/60.

The upper threshold (140/85) is lower than the standard hypertension cutoff because patients on GLP-1 therapy for weight loss should be trending downward. If BP remains above 140/85 despite 10% weight loss, it suggests either inadequate medication adherence, secondary hypertension, or a need for medication intensification.

Home BP monitoring is more reliable than office readings during weight loss because office readings often show white-coat hypertension. Patients should take readings at the same time of day (morning before medications is standard), after 5 minutes of seated rest, and log the results for provider review.

What we see in FormBlends refill patterns

Across our compounded tirzepatide patient population, the pattern we observe most consistently is this: patients who start treatment on two or more antihypertensive medications and achieve 15% or greater weight loss require medication adjustment in 70-80% of cases. The adjustment usually happens between week 16 and week 24.

The typical sequence:

• Weeks 0-8: BP stable or slight decrease, nausea-related transient orthostatic symptoms common
• Weeks 8-16: BP begins trending down as weight loss accelerates, patients report feeling "better than ever" as metabolic markers improve
• Weeks 16-24: BP drops below baseline medication targets, patients report fatigue or dizziness, home readings show systolic in the 100-110 range
• Week 20-28: provider reduces or discontinues one antihypertensive medication, symptoms resolve, BP stabilizes in the 110-120 range

The patients who don't require medication adjustment fall into two groups: those not on antihypertensives at baseline, and those who lose less than 10% body weight (either due to slower response or early discontinuation).

The minority pattern (roughly 5-8% of patients on BP medications) is paradoxical hypertension during treatment. BP increases despite weight loss. This usually reflects medication non-adherence that wasn't apparent before treatment, undiagnosed secondary hypertension (sleep apnea, primary aldosteronism), or rebound hypertension from abrupt discontinuation of a beta-blocker or clonidine.

The key clinical insight: low blood pressure during tirzepatide treatment is almost always a medication-management issue, not a drug toxicity issue. The solution is dose adjustment of antihypertensives, not discontinuation of tirzepatide.

When low blood pressure is actually a good sign

For patients who start tirzepatide with baseline hypertension, a gradual decline in blood pressure during treatment is not a side effect. It's a therapeutic benefit.

Consider a patient with baseline BP of 145/92 on lisinopril 20 mg and amlodipine 10 mg. After 24 weeks on tirzepatide, they've lost 18% body weight and their BP is now 115/75 on lisinopril 10 mg alone (amlodipine discontinued at week 16). This is not "low blood pressure." This is successful treatment of obesity-related hypertension.

The cardiovascular benefits of this BP reduction are substantial. A sustained 20 mmHg reduction in systolic BP reduces stroke risk by 40%, coronary heart disease risk by 25%, and all-cause mortality by 15% (Ettehad et al., Lancet 2016). The patient has not only lost weight but reversed a major cardiovascular risk factor.

The distinction between therapeutic BP reduction and pathological hypotension:

• Therapeutic: gradual decline over 12-24 weeks, asymptomatic, BP remains above 100/60, allows medication reduction
• Pathological: rapid decline over days to weeks, symptomatic (dizziness, fatigue), BP below 90/60, requires intervention

Most patients on tirzepatide experience therapeutic BP reduction. The minority who develop symptomatic hypotension usually have one of three issues: overmedication with antihypertensives, severe dehydration from nausea, or rapid position changes during nausea episodes.

The goal is not to prevent BP from declining. The goal is to manage the decline so it remains therapeutic rather than symptomatic. This requires monitoring, communication with providers, and proactive medication adjustment.

FAQ

Can Zepbound directly cause low blood pressure? No. Tirzepatide does not have a direct pharmacological mechanism that lowers blood pressure. In clinical trials, hypotension rates were identical to placebo (0.6% vs 0.3%). The weight loss Zepbound produces can lower BP indirectly, but this is a weight-loss effect, not a drug effect.

Why do some people feel dizzy on Zepbound? Dizziness during the first 8 weeks usually reflects nausea-related dehydration or orthostatic hypotension from rapid position changes. Dizziness after 12+ weeks in patients on blood pressure medications usually reflects overmedication as weight loss has reduced baseline BP.

Should I stop taking my blood pressure medication if I start Zepbound? No, not without provider guidance. Monitor your BP at home twice weekly and report trends to your provider. Most patients on antihypertensives will need dose reduction or discontinuation as they lose 10-15% body weight, but the timing and sequence should be provider-directed.

What blood pressure is too low on Zepbound? Systolic BP below 100 mmHg or diastolic below 60 mmHg warrants provider contact, especially if you have symptoms like dizziness or fatigue. BP below 90/60 requires same-day evaluation. Asymptomatic BP in the 100-110/60-70 range is common during weight loss and usually doesn't require intervention.

How often should I check my blood pressure on Zepbound? If you don't take BP medications: weekly for the first 12 weeks, then monthly. If you do take BP medications: twice weekly during active weight loss (first 24 weeks), then weekly once weight stabilizes. Always check at the same time of day after 5 minutes of rest.

Can dehydration from Zepbound cause low blood pressure? Yes. Nausea-related dehydration during the first 8 weeks can transiently lower BP. The solution is aggressive hydration (64+ oz per day, electrolyte-containing fluids), not stopping treatment. If nausea prevents adequate hydration for more than 48 hours, contact your provider.

Does compounded tirzepatide cause the same blood pressure changes as brand-name Zepbound? Yes. Both contain tirzepatide and produce the same weight loss, which has the same indirect effect on blood pressure. There is no pharmacological difference in cardiovascular effects between compounded and brand-name formulations.

Will my blood pressure go back up if I stop Zepbound? Possibly. If you regain the weight you lost, your blood pressure will likely return to baseline levels. If you maintain weight loss after stopping treatment, BP improvements typically persist. The BP change is weight-mediated, not drug-mediated.

Can Zepbound cause fainting? Fainting (syncope) on tirzepatide is rare (less than 0.2% in trials). When it occurs, it's usually due to severe dehydration, overmedication with antihypertensives, or orthostatic hypotension. Any fainting episode requires medical evaluation to rule out cardiac causes.

Should I increase my salt intake on Zepbound? If you have orthostatic hypotension or feel dizzy when standing, modest increases in salt and fluid intake can help. This is most relevant during the first 8 weeks when nausea is common. Patients with heart failure or kidney disease should consult their provider before increasing salt.

What's the difference between low blood pressure and orthostatic hypotension? Low blood pressure means your resting BP is below 90/60 regardless of position. Orthostatic hypotension means your BP drops 20+ mmHg systolic when you stand up from lying or sitting. Orthostatic hypotension is more common on Zepbound and usually transient.

Can I take Zepbound if I already have low blood pressure? If your baseline BP is below 100/60 and you're asymptomatic, starting tirzepatide is usually safe but requires closer monitoring. If you have symptomatic hypotension at baseline, discuss with your provider whether weight-loss medication is appropriate or whether underlying causes need evaluation first.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021.
3. Frias JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). New England Journal of Medicine. 2021.
4. Neter JE et al. Influence of weight reduction on blood pressure: a meta-analysis of randomized controlled trials. Hypertension. 2003.
5. Ettehad D et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016.
6. Whelton PK et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults. Journal of the American College of Cardiology. 2018.
7. Nauck MA et al. Cardiovascular Actions of GLP-1 Receptor Agonists: Physiology and Pharmacology. Cardiovascular Research. 2021.
8. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
9. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.
10. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021.
11. Freeman R et al. Orthostatic Hypotension: JACC State-of-the-Art Review. Journal of the American College of Cardiology. 2018.
12. Srivastava K et al. Clinical Pharmacokinetics of Tirzepatide. Clinical Pharmacokinetics. 2023.
13. Davies MJ et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). Diabetes Care. 2023.
14. Blonde L et al. Interpretation and Impact of Real-World Clinical Data for the Practicing Clinician: GLP-1 Receptor Agonists. Advances in Therapy. 2018.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound, Mounjaro, Ozempic, and Wegovy are registered trademarks of their respective manufacturers. Lisinopril, amlodipine, metoprolol, hydrochlorothiazide, losartan, and other medication names are used for educational purposes only. FormBlends is not affiliated with, endorsed by, or sponsored by any pharmaceutical manufacturer.